Welcome to our dedicated page for Biomarin Pharmaceutical news (Ticker: BMRN), a resource for investors and traders seeking the latest updates and insights on Biomarin Pharmaceutical stock.
BioMarin Pharmaceutical Inc. develops and commercializes medicines for rare genetic diseases, with recurring news centered on commercial portfolio performance, regulatory approvals, clinical data and business development. Company updates commonly reference therapies for achondroplasia, phenylketonuria, hemophilia, mucopolysaccharidosis and lysosomal storage diseases, including VOXZOGO, PALYNZIQ, GALAFOLD and POMBILITI + OPFOLDA.
BioMarin news also covers financial results, guidance, acquisition integration, debt financing and governance changes. Clinical and regulatory announcements focus on genetically defined conditions, skeletal disorders, enzyme-based therapies and investigational rare-disease programs such as DMX-200 for focal segmental glomerulosclerosis.
BioMarin Pharmaceutical (BMRN) announced a preclinical collaboration with Deep Genomics on November 17, 2020, to enhance drug discovery using AI technology. The partnership focuses on identifying oligonucleotide drug candidates for four rare diseases with significant unmet needs. Financial terms remain undisclosed, but Deep Genomics will receive an upfront payment and potential development milestones. This collaboration aims to leverage AI for faster identification and validation of therapeutic candidates, aiming to expedite BioMarin's development pipeline in rare disease treatments.
BioMarin Pharmaceutical (NASDAQ: BMRN) announced its participation in three upcoming virtual investor conferences on November 12, 2020. Management will be presenting, and an audio webcast will be available live on their website. Archived versions of the presentations will be accessible for a limited time post-conference. BioMarin focuses on developing innovative therapies for serious rare disorders and has a strong portfolio with six commercialized products and ongoing clinical candidates. Further details can be found on their official website.
BioMarin Pharmaceutical (NASDAQ:BMRN) has announced the expansion of its clinical program for vosoritide with two new Phase 2 studies targeting children with achondroplasia and other genetic forms of short stature. The first study will assess the safety of vosoritide in infants at risk of life-threatening foramen magnum compression. The second, an investigator-initiated study by Children's National Hospital, will explore vosoritide’s effects on growth in selected genetic short stature patients. Both studies aim to enroll a significant number of participants, aiming to enhance treatment outcomes.
BioMarin Pharmaceutical reported Q3 2020 financial results with total revenues of $476.8 million, up by 3% from Q3 2019. Net product revenues increased by 2% to $460.7 million. The company achieved a substantial GAAP net income of $784.8 million, largely due to a $800.8 million tax benefit related to IP transfer. However, revenues from products like Vimizim and Naglazyme declined. Despite COVID-19 challenges affecting revenues, BioMarin remains optimistic about upcoming regulatory filings for its gene therapies, valoctocogene roxaparvovec and vosoritide. Cash reserves stood at $1.77 billion.
BioMarin Pharmaceutical (NASDAQ: BMRN) announced that its CEO, Jean-Jacques Bienaimé, and CFO, Brian Mueller, will participate in the Credit Suisse 29th Annual Virtual Healthcare Conference on November 10, 2020, at 12:30 PM ET. An audio webcast will be available live and can be accessed here. An archived version will also be accessible on the company's website afterward. BioMarin develops innovative therapies for serious rare disorders and has six commercialized products along with several candidates in the pipeline.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that the FDA has accepted its New Drug Application (NDA) for vosoritide, a treatment for achondroplasia, marking the first marketing application for this condition in the U.S. The PDUFA action date is set for Aug. 20, 2021. The company believes that the outcomes from its prior clinical trials support the application's validity. Additionally, BioMarin is nearing completion of enrollment for a Phase 2 study involving infants with achondroplasia, focusing on safety and height Z-scores.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host a conference call and webcast on November 5, 2020, at 4:30 p.m. ET to discuss its third quarter 2020 financial results and provide a business update. The call can be accessed via U.S. and international dial-in numbers, with a conference ID of 3291898. A replay will be available for one week after the call. BioMarin focuses on innovative therapies for serious rare genetic diseases, offering six commercial products and various clinical candidates.
BioMarin Pharmaceutical has received FDA approval for an increased maximum dose of 60 mg for its PKU treatment, Palynziq. Previously capped at 40 mg, this new dosage accommodates approximately 19% of participants from Phase 3 PRISM studies requiring higher doses. The label expansion includes long-term efficacy data showing sustained reductions in blood Phe levels, with 66% of participants achieving optimal levels after two years. BioMarin's ongoing commitment to the PKU community is evident as they continue to research and develop innovative therapies.
BioMarin Pharmaceutical has appointed Kevin Eggan, Ph.D., a MacArthur Fellowship winner, as the new Group Vice President for Research and Early Development as of October 5, 2020. With nearly two decades of expertise in rare neurological disorders, Dr. Eggan is expected to lead BioMarin's innovative research in genetic therapies. He aims to enhance drug discovery processes and ensure a robust pipeline of therapies for rare genetic diseases. Dr. Eggan joins from Harvard University, holding a strong publication record and numerous patents, and his arrival is set to bolster BioMarin's strategic vision.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has received Fast Track designation from the U.S. FDA for BMN 307, a gene therapy aimed at treating phenylketonuria (PKU). This designation will expedite the drug's development and review processes. The company's Phase 1/2 study, Phearless, is underway, evaluating the safety and efficacy of a single dose of BMN 307. With over 15 years in PKU research and two existing therapies, BioMarin aims to provide further treatment options. The Fast Track status may allow for Accelerated Approval and Priority Review.